MENU
+Compare
ALPMY
Stock ticker: OTC
AS OF
May 9 closing price
Price
$9.58
Change
-$0.08 (-0.83%)
Capitalization
26.55B

ALPMY Astellas Pharma, Inc. Forecast, Technical & Fundamental Analysis

Astellas Pharma Inc is a specialty global pharmaceutical company... Show more

ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ALPMY with price predictions
May 09, 2025

ALPMY's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for ALPMY moved out of overbought territory on April 30, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ALPMY as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ALPMY turned negative on May 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

ALPMY moved below its 50-day moving average on May 08, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALPMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALPMY broke above its upper Bollinger Band on April 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for ALPMY crossed bullishly above the 50-day moving average on April 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPMY advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 188 cases where ALPMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.427) is normal, around the industry mean (5.632). P/E Ratio (37.594) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.030) settles around the average of (0.161) among similar stocks. P/S Ratio (2.448) is also within normal values, averaging (3.643).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALPMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

View a ticker or compare two or three
ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ALPMY is expected to report earnings to fall 42.34% to 16 cents per share on July 30

Astellas Pharma, Inc. ALPMY Stock Earnings Reports
Q2'25
Est.
$0.17
Q1'25
Beat
by $0.16
Q4'24
Missed
by $0.41
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.08
The last earnings report on April 25 showed earnings per share of 29 cents, beating the estimate of 13 cents. With 76.08K shares outstanding, the current market capitalization sits at 26.55B.
A.I.Advisor
published Dividends

ALPMY paid dividends on June 17, 2024

Astellas Pharma, Inc. ALPMY Stock Dividends
А dividend of $0.22 per share was paid with a record date of June 17, 2024, and an ex-dividend date of March 27, 2024. Read more...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
2-5-1, Nihonbashi-Honcho
Phone
+81 332443000
Employees
16243
Web
http://www.astellas.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GRHIX13.540.25
+1.88%
Goehring & Rozencwajg Resources Instl
MGKCX11.720.13
+1.12%
Morgan Stanley Global Permanence C
FDETX23.960.03
+0.13%
Fidelity Advisor Capital Development O
STREX21.38N/A
N/A
Sterling Capital Equity Income R6
RSMRX14.62-0.13
-0.88%
RBC SMID Cap Growth R6

ALPMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPMY has been loosely correlated with ALPMF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPMY jumps, then ALPMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPMY
1D Price
Change %
ALPMY100%
-0.83%
ALPMF - ALPMY
38%
Loosely correlated
-7.88%
OPHLY - ALPMY
33%
Loosely correlated
-0.85%
CHGCY - ALPMY
22%
Poorly correlated
-1.47%
DSNKY - ALPMY
21%
Poorly correlated
-2.20%
OTSKY - ALPMY
20%
Poorly correlated
-2.64%
More